Relation of Body Mass Index With Adverse Outcomes Among Patients With Atrial Fibrillation: A Meta-Analysis and Systematic Review

Journal of the American Heart Association

Volumn 5, Issue 9, 2016, Pages

  Zhu, Wengen ^a   Wan, Rong ^b   Liu, Fuwei ^a   Hu, Jinzhu ^a   Huang, Lin ^a   Li, Juxiang ^a   Hong, Kui ^a,b  

^a NANCHANG UNIVERSITY   (China)

^b Jiangxi Key Laboratory of Molecular Medicine   (China)

Author keywords

Atrial fibrillation; Body mass index; Death; Prognosis; Stroke; Systemic embolism

Indexed keywords

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; ATRIAL FIBRILLATION; BODY MASS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DISEASE ASSOCIATION; EMBOLISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MIDDLE AGED; OBESITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SYSTEMATIC REVIEW; UNDERWEIGHT; VERY ELDERLY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COMPLICATION; MORTALITY; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

ATRIAL FIBRILLATION; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; EMBOLISM; HUMANS; MORTALITY; OBESITY; OVERWEIGHT; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STROKE; THINNESS;

EID: 85032046559     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.116.004006     Document Type: Article

References (72)

1. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119-125.
2. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113:359-364.
3. Karasoy D, Bo JT, Hansen ML, Schmiegelow M, Lamberts M, Gislason GH, Hansen J, Torp-Pedersen C, Olesen JB. Obesity is a risk factor for atrial fibrillation among fertile young women: a nationwide cohort study. Europace. 2013;15:781-786.
4. Wang TJ, Parise H, Levy D, D'Agostino RS, Wolf PA, Vasan RS, Benjamin EJ. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292:2471-2477.
5. Tedrow UB, Conen D, Ridker PM, Cook NR, Koplan BA, Manson JE, Buring JE, Albert CM. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (Women's Health Study). J Am Coll Cardiol. 2010;55:2319-2327.
6. Guglin M, Maradia K, Chen R, Curtis AB. Relation of obesity to recurrence rate and burden of atrial fibrillation. Am J Cardiol. 2011;107:579-582.
7. Tsang TSM, Barnes ME, Miyasaka Y, Cha SS, Bailey KR, Verzosa GC, Seward JB, Gersh BJ. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur Heart J. 2008;29:2227-2233.
8. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309:71-82.
9. Carnethon MR, Rasmussen-Torvik LJ, Palaniappan L. The obesity paradox in diabetes. Curr Cardiol Rep. 2014;16:446.
10. Carnethon MR, De Chavez PJ, Biggs ML, Lewis CE, Pankow JS, Bertoni AG, Golden SH, Liu K, Mukamal KJ, Campbell-Jenkins B, Dyer AR. Association of weight status with mortality in adults with incident diabetes. JAMA. 2012;308:581-590.
11. Mohebi R, Simforoosh A, Tohidi M, Azizi F, Hadaegh F. Obesity paradox and risk of mortality events in chronic kidney disease patients: a decade of follow-up in Tehran lipid and glucose study. J Ren Nutr. 2015;25:345-350.
12. Rhee CM, Ahmadi SF, Kalantar-Zadeh K. The dual roles of obesity in chronic kidney disease: a review of the current literature. Curr Opin Nephrol Hypertens. 2016;25:208-216.
13. Andersen KK, Olsen TS. The obesity paradox in stroke: lower mortality and lower risk of readmission for recurrent stroke in obese stroke patients. Int J Stroke. 2015;10:99-104.
14. Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, Mookadam F, Lopez-Jimenez F. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006;368:666-678.
15. Uretsky S, Messerli FH, Bangalore S, Champion A, Cooper-Dehoff RM, Zhou Q, Pepine CJ. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med. 2007;120:863-870.
16. Sharma A, Lavie CJ, Borer JS, Vallakati A, Goel S, Lopez-Jimenez F, Arbab-Zadeh A, Mukherjee D, Lazar JM. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol. 2015;115:1428-1434.
17. Novo G, Mansueto P, La Franca ML, Di Leo R, Di Rosa S, Fazio G, Mansueto S, Ferrara F, Novo S. Risk factors, atrial fibrillation and thromboembolic events. Int Angiol. 2008;27:433-438.
18. Overvad TF, Rasmussen LH, Skjoth F, Overvad K, Lip GY, Larsen TB. Body mass index and adverse events in patients with incident atrial fibrillation. Am J Med. 2013;126:640-649.
19. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, Lorimer MF, Lau DH, Antic NA, Brooks AG, Abhayaratna WP, Kalman JM, Sanders P. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310:2050-2060.
20. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, Twomey D, Elliott AD, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015;65:2159-2169.
21. Yanagisawa S, Inden Y, Yoshida N, Kato H, Miyoshi-Fujii A, Mizutani Y, Ito T, Kamikubo Y, Kanzaki Y, Hirai M, Murohara T. Body mass index is associated with prognosis in Japanese elderly patients with atrial fibrillation: an observational study from the outpatient clinic. Heart Vessels. 2016;31:1553-1561.
22. Wang J, Yang Y, Zhu J, Zhang H, Shao X, Tian L, Huang B, Yu L, Gao X, Wang M. Overweight is associated with improved survival and outcomes in patients with atrial fibrillation. Clin Res Cardiol. 2014;103:533-542.
23. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012.
24. Gu WJ, Wang F, Tang L, Liu JC. Single-dose etomidate does not increase mortality in patients with sepsis: a systematic review and meta-analysis of randomized controlled trials and observational studies. Chest. 2015;147:335-346.
25. Obesity: preventing and managing the global epidemic. Report of a WHO consultation (WHO Technical Report Series 894). World Health Organ Tech Rep Ser. 2000;894:1-253.
26. Wells GA, Shea B, O Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. 2014. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed May 30, 2016.
27. Goel K, Lopez-Jimenez F, De Schutter A, Coutinho T, Lavie CJ. Obesity paradox in different populations: evidence and controversies. Future Cardiol. 2014;10:81-91.
28. Lavie CJ, De Schutter A, Parto P, Jahangir E, Kokkinos P, Ortega FB, Arena R, Milani RV. Obesity and prevalence of cardiovascular diseases and prognosis-the obesity paradox updated. Prog Cardiovasc Dis. 2016;58:537-547.
29. Badheka AO, Rathod A, Bharadwaj A, Afonso L, Jacob S. Obesity paradox in outcomes of atrial fibrillation. Am J Cardiol. 2011;108:474.
30. Chu C, Lee W, Hsu P, Lee M, Lee H, Chiu C, Lin T, Lee C, Yen H, Voon W, Lai W, Sheu S, Su H. Association of increased epicardial adipose tissue thickness with adverse cardiovascular outcomes in patients with atrial fibrillation. Medicine. 2016;95:e2874.
31. Proietti M, Raparelli V, Basili S, Olshansky B, Lip GY. Relation of female sex to left atrial diameter and cardiovascular death in atrial fibrillation: the AFFIRM Trial. Int J Cardiol. 2016;207:258-263.
32. Lee WH, Hsu PC, Chu CY, Lee HH, Lee MK, Lee CS, Yen HW, Lin TH, Voon WC, Lai WT, Sheu SH, Su HM. Anemia as an independent predictor of adverse cardiac outcomes in patients with atrial fibrillation. Int J Med Sci. 2015;12:618-624.
33. van den Ham HA, Klungel OH, Singer DE, Leufkens HG, van Staa TP. Comparative performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk scores predicting stroke in patients with atrial fibrillation: results from a national primary care database. J Am Coll Cardiol. 2015;66:1851-1859.
34. Senoo K, Lip GYH. Body mass index and adverse outcomes in elderly patients with atrial fibrillation: The AMADEUS Trial. Stroke. 2016;47:523-526.
35. Hamatani Y, Yamashita Y, Esato M, Chun Y, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GYH, Akao M. Predictors for stroke and death in non-anticoagulated Asian patients with atrial fibrillation: the Fushimi AF Registry. PLoS One. 2015;10:e142394.
36. Badheka AO, Rathod A, Kizilbash MA, Garg N, Mohamad T, Afonso L, Jacob S. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med. 2010;123:646-651.
37. Sandhu RK, Ezekowitz J, Andersson U, Alexander JH, Granger CB, Halvorsen S, Hanna M, Hijazi Z, Jansky P, Lopes RD, Wallentin L. The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J. 2016. Available at: http://eurheartj.oxfordjournals.org/content/early/2016/04/11/eurheartj.ehw124. Accessed September 2, 2016.
38. Proietti M, Lane DA, Lip GYH. Relation of non-valvular atrial fibrillation to body mass index (from the SPORTIF Trials). Am J Cardiol. 2016;118:72-78.
39. Kwon Y, Norby FL, Jensen PN, Agarwal SK, Soliman EZ, Lip GY, Longstreth WJ, Alonso A, Heckbert SR, Chen LY. Association of smoking, alcohol, and obesity with cardiovascular death and ischemic stroke in atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) Study and Cardiovascular Health Study (CHS). PLoS One. 2016;11:e147065.
40. Wang H, Si Q, Shan Z, Guo Y, Lin K, Zhao X, Wang Y. Effects of body mass index on risks for ischemic stroke, thromboembolism, and mortality in Chinese atrial fibrillation patients: a single-center experience. PLoS One. 2015;10:e123516.
41. Pandey A, Gersh BJ, McGuire DK, Shrader P, Thomas L, Kowey PR, Mahaffey KW, Hylek E, Sun S, Burton P, Piccini J, Peterson E, Fonarow GC. Association of body mass index with care and outcomes in patients with atrial fibrillation: results from the ORBIT-AF Registry. JACC Clin Electrophysiol. 2016;2:355-363.
42. Hamatani Y, Ogawa H, Uozumi R, Iguchi M, Yamashita Y, Esato M, Chun Y, Tsuji H, Wada H, Hasegawa K, Abe M, Morita S, Akao M. Low body weight is associated with the incidence of stroke in atrial fibrillation patients-insight from the Fushimi AF Registry. Circ J. 2015;79:1009-1017.
43. Ardestani A, Hoffman HJ, Cooper HA. Obesity and outcomes among patients with established atrial fibrillation. Am J Cardiol. 2010;106:369-373.
44. Inoue H, Kodani E, Atarashi H, Okumura K, Yamashita T, Origasa H. Impact of body mass index on the prognosis of Japanese patients with non-valvular atrial fibrillation. Am J Cardiol. 2016;118:215-221.
45. Park DW, Kim YH, Yun SC, Ahn JM, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Park SW, Park SJ. Association of body mass index with major cardiovascular events and with mortality after percutaneous coronary intervention. Circ Cardiovasc Interv. 2013;6:146-153.
46. Higashi Y, Sasaki S, Nakagawa K, Kimura M, Noma K, Sasaki S, Hara K, Matsuura H, Goto C, Oshima T, Chayama K, Yoshizumi M. Low body mass index is a risk factor for impaired endothelium-dependent vasodilation in humans: role of nitric oxide and oxidative stress. J Am Coll Cardiol. 2003;42:256-263.
47. Nakajima K, Yamaoka H, Morita K, Ebata M, Eguchi S, Muneyuki T, Munakata H. Elderly people with low body weight may have subtle low-grade inflammation. Obesity (Silver Spring). 2009;17:803-808.
48. Novo G, Guttilla D, Fazio G, Cooper D, Novo S. The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS. Br J Clin Pharmacol. 2008;66:345-351.
49. Ermakov S, Azarbal F, Stefanick ML, LaMonte MJ, Li W, Tharp KM, Martin LW, Nassir R, Salmoirago-Blotcher E, Albert CM, Manson JE, Assimes TL, Hlatky MA, Larson JC, Perez MV. The associations of leptin, adiponectin and resistin with incident atrial fibrillation in women. Heart. 2016;102:1354-1362.
50. Li G, Liu T. The therapeutic strategies of enhancing adiponectin and lowering leptin may be benefit to controlling atrial fibrillation. Med Hypotheses. 2009;73:122.
51. Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest. 1997;100:270-278.
52. Franceschini R, Tenconi GL, Zoppoli F, Barreca T. Endocrine abnormalities and outcome of ischaemic stroke. Biomed Pharmacother. 2001;55:458-465.
53. Cohoon KP, McBane RD, Ammash N, Slusser JP, Grill DE, Wysokinski WE. Relationship between body mass index and left atrial appendage thrombus in nonvalvular atrial fibrillation. J Thromb Thrombolysis. 2016;41:613-618.
54. Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation and obesity-results of a meta-analysis. Am Heart J. 2008;155:310-315.
55. Nalliah CJ, Sanders P, Kottkamp H, Kalman JM. The role of obesity in atrial fibrillation. Eur Heart J. 2016;37:1565-1572.
56. Weber MA, Neutel JM, Smith DH. Contrasting clinical properties and exercise responses in obese and lean hypertensive patients. J Am Coll Cardiol. 2001;37:169-174.
57. Davos CH, Doehner W, Rauchhaus M, Cicoira M, Francis DP, Coats AJ, Clark AL, Anker SD. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail. 2003;9:29-35.
58. Lee SH, Chen YC, Chen YJ, Chang SL, Tai CT, Wongcharoen W, Yeh HI, Lin CI, Chen SA. Tumor necrosis factor-alpha alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes. Life Sci. 2007;80:1806-1815.
59. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, Lopes RD, McMurray JJ, Granger CB. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol. 2013;61:2274-2284.
60. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594-600.
61. Piepoli MF, Corra U, Veglia F, Bonomi A, Salvioni E, Cattadori G, Metra M, Lombardi C, Sinagra G, Limongelli G, Raimondo R, Re F, Magri D, Belardinelli R, Parati G, Mina C, Scardovi AB, Guazzi M, Cicoira M, Scrutinio D, Di Lenarda A, Bussotti M, Frigerio M, Correale M, Villani GQ, Paolillo S, Passino C, Agostoni P. Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: data from the MECKI Score Research Group. Eur J Heart Fail. 2016;18:545-553.
62. Lavie CJ, Cahalin LP, Chase P, Myers J, Bensimhon D, Peberdy MA, Ashley E, West E, Forman DE, Guazzi M, Arena R. Impact of cardiorespiratory fitness on the obesity paradox in patients with heart failure. Mayo Clin Proc. 2013;88:251-258.
63. Clark AL, Fonarow GC, Horwich TB. Impact of cardiorespiratory fitness on the obesity paradox in patients with systolic heart failure. Am J Cardiol. 2015;115:209-213.
64. McAuley PA, Artero EG, Sui X, Lee DC, Church TS, Lavie CJ, Myers JN, Espana-Romero V, Blair SN. The obesity paradox, cardiorespiratory fitness, and coronary heart disease. Mayo Clin Proc. 2012;87:443-451.
65. Huxley RR, Misialek JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY, Alonso A. Physical activity, obesity, weight change, and risk of atrial fibrillation: the Atherosclerosis Risk in Communities study. Circ Arrhythm Electrophysiol. 2014;7:620-625.
66. Grundvold I, Skretteberg PT, Liestol K, Gjesdal K, Erikssen G, Kjeldsen SE, Arnesen H, Erikssen J, Bodegard J. Importance of physical fitness on predictive effect of body mass index and weight gain on incident atrial fibrillation in healthy middle-age men. Am J Cardiol. 2012;110:425-432.
67. Zhu W, Shen Y, Zhou Q, Xu Z, Huang L, Chen Q, Hong K. Association of physical fitness with the risk of atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol. 2016;39:421-428.
68. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Hendriks JM, Twomey D, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study. J Am Coll Cardiol. 2015;66:985-996.
69. Lajous M, Banack HR, Kaufman JS, Hernan MA. Should patients with chronic disease be told to gain weight? The obesity paradox and selection bias. Am J Med. 2015;128:334-336.
70. Banack HR, Kaufman JS. Does selection bias explain the obesity paradox among individuals with cardiovascular disease? Ann Epidemiol. 2015;25:342-349.
71. Menezes AR, Lavie CJ, De Schutter A, Milani RV, O'Keefe J, DiNicolantonio JJ, Morin DP, Abi-Samra FM. Lifestyle modification in the prevention and treatment of atrial fibrillation. Prog Cardiovasc Dis. 2015;58:117-125.
72. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, Alasady M, Hanley L, Antic NA, McEvoy RD, Kalman JM, Abhayaratna WP, Sanders P. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014;64:2222-2231.